Cell cycle signaling is a well‐known regulator of tumor development and drug resistance.[38] Targeting these pathways has been shown to improve clinical outcomes, including prolonged survival and enhanced therapeutic responses,[39, 40, 41] even for cancers that are resistant to PARPi.[42, 43, 44, 45, 46] Specifically, our drug screening identified CDC7, a protein crucial for the G1/S phase transition and DNA replication, as a potential target. Here, CDC7 is linked to neoplasm.